Interferons at age 50: past, current and future impact on biomedicine

The family of interferon (IFN) proteins has now more than reached the potential envisioned by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical effectiveness against both RNA and DNA viruses, but are also the prototypic biological response modifiers for oncology, and show effectiveness in suppressing manifestations of multiple sclerosis. Studies of IFNs have resulted in fundamental insights into cellular signalling mechanisms, gene transcription and innate and acquired immunity. Further elucidation of the multitude of IFN-induced genes, as well as drug development strategies targeting IFN production via the activation of the Toll-like receptors (TLRs), will almost certainly lead to newer and more efficacious therapeutics. Our goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential.

[1]  C. Alpers,et al.  Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  H. Thomas,et al.  MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1989, The Lancet.

[3]  T. Merigan,et al.  Systemic alpha‐interferon therapy of multiple sclerosis , 1984, Neurology.

[4]  E. Borden.  Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. , 2007, Cytokine & growth factor reviews.

[5]  J. Frank,et al.  The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis , 1995, Annals of neurology.

[6]  E. Borden,et al.  Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. , 1987, Cancer research.

[7]  J. Casanova,et al.  Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. , 1999, Experimental hematology.

[8]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[9]  J. Houghton,et al.  Modulation of the Fas Signaling Pathway by IFN-γ in Therapy of Colon Cancer: Phase I Trial and Correlative Studies of IFN-γ, 5-Fluorouracil, and Leucovorin , 2002 .

[10]  M. Stanley,et al.  A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. , 1998, The Journal of infectious diseases.

[11]  E. Borden,et al.  Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine. , 1990, Cancer research.

[12]  Hua Lu,et al.  Interferon-inducible protein IFIXalpha1 functions as a negative regulator of HDM2. , 2006, Molecular and cellular biology.

[13]  A. Ascherio,et al.  Environmental risk factors for multiple sclerosis. Part I: The role of infection , 2007, Annals of neurology.

[14]  D. Levy,et al.  The nucleoporin Nup96 is required for proper expression of interferon-regulated proteins and functions. , 2006, Immunity.

[15]  H. Balfour,et al.  Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-α2B and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection , 1999 .

[16]  C. Schindler,et al.  Stat2-Dependent Regulation of MHC Class II Expression1 , 2007, The Journal of Immunology.

[17]  R. Moore,et al.  Imiquimod for the treatment of genital warts: a quantitative systematic review , 2001, BMC infectious diseases.

[18]  M. Katze,et al.  Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. , 1998, Pharmacology & therapeutics.

[19]  K. Cantell,et al.  Combination therapy for dendritic keratitis with acyclovir and alpha-interferon. , 1983, Archives of ophthalmology.

[20]  Naděžda Brdičková,et al.  CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs , 2006, Nature.

[21]  T. Maniatis,et al.  IKKε and TBK1 are essential components of the IRF3 signaling pathway , 2003, Nature Immunology.

[22]  R. Silverman,et al.  2-5A-dependent RNase Molecules Dimerize during Activation by 2-5A (*) , 1995, The Journal of Biological Chemistry.

[23]  F. Hayden,et al.  Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds , 1988, Antimicrobial Agents and Chemotherapy.

[24]  P. Pandolfi,et al.  PML mediates the interferon‐induced antiviral state against a complex retrovirus via its association with the viral transactivator , 2001, The EMBO journal.

[25]  M. Kasuga,et al.  IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. , 2003, Carcinogenesis.

[26]  W. Boll,et al.  Mx protein: Constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus , 1986, Cell.

[27]  J. Kirkwood,et al.  Homozygous deletions within human chromosome band 9p21 in melanoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Dennis,et al.  Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.

[29]  G. Stark,et al.  Complex modulation of cell type-specific signaling in response to type I interferons. , 2006, Immunity.

[30]  D. Levy,et al.  JAK-STAT Signaling: From Interferons to Cytokines* , 2007, Journal of Biological Chemistry.

[31]  P. Weck,et al.  Interferons in the treatment of genital human papillomavirus infections. , 1988, The American journal of medicine.

[32]  B. Zetter,et al.  Inhibition of cell motility by interferon. , 1980, Science.

[33]  C. D. Krause,et al.  Interferons, interferon‐like cytokines, and their receptors , 2004, Immunological reviews.

[34]  M. Baccarani,et al.  Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. , 2001, Blood.

[35]  E. Fikrig,et al.  Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis , 2004, Nature Medicine.

[36]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[37]  R. Aebersold,et al.  The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  F. Belardelli,et al.  Anti‐tumor effects of interferon in mice injected with interferonsensitive and interferon‐resistant friend leukemia cells. VI. Adjuvant therapy after surgery in the inhibition of liver and spleen metastases , 1987, International journal of cancer.

[39]  L. Jacobs,et al.  Intrathecal interferon reduces exacerbations of multiple sclerosis. , 1981, Science.

[40]  K. Cantell,et al.  Interferon therapy in juvenile laryngeal papillomatosis. , 1981, Archives of otolaryngology.

[41]  Aseem Kumar,et al.  Defective TNF-α-Induced Apoptosis in STAT1-Null Cells Due to Low Constitutive Levels of Caspases , 1997 .

[42]  J. Heathcote,et al.  Treatment of hepatitis C , 2005, Journal of viral hepatitis.

[43]  B. Finlay,et al.  Anti-Immunology: Evasion of the Host Immune System by Bacterial and Viral Pathogens , 2006, Cell.

[44]  C. Bucana,et al.  Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. , 1998, Cancer research.

[45]  L. Jermiin,et al.  Characterization of the type I interferon locus and identification of novel genes. , 2004, Genomics.

[46]  R. Silverman,et al.  Small self-RNA generated by RNase L amplifies antiviral innate immunity , 2007, Nature.

[47]  R. Rudick,et al.  Defining interferon β response status in multiple sclerosis patients , 2004 .

[48]  P. Cresswell.  Intracellular Surveillance: Controlling the Assembly of MHC Class I‐Peptide Complexes , 2000, Traffic.

[49]  J. Kirkwood,et al.  Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  F. Hayden,et al.  Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds , 1984, Antimicrobial Agents and Chemotherapy.

[51]  G. Blobel,et al.  Role of Nucleoporin Induction in Releasing an mRNA Nuclear Export Block , 2002, Science.

[52]  J. Dambrosia,et al.  Increases in soluble VCAM‐1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β‐1b , 1997, Annals of neurology.

[53]  J. Uhm,et al.  Interferon β‐1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase‐9 , 1996 .

[54]  M. Sy,et al.  Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. , 1998, Cancer research.

[55]  W. Alexander,et al.  The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. , 2004, Annual review of immunology.

[56]  P. Moore,et al.  Interferon-κ, a Novel Type I Interferon Expressed in Human Keratinocytes* , 2001, The Journal of Biological Chemistry.

[57]  Jacob Piehler,et al.  Determination of the two-dimensional interaction rate constants of a cytokine receptor complex. , 2006, Biophysical journal.

[58]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[59]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[60]  M. Fellous,et al.  A protein tyrosine kinase in the interferon α β signaling pathway , 1992, Cell.

[61]  S. Akira,et al.  The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis , 2007, The Journal of experimental medicine.

[62]  E. Borden,et al.  Identification of X-linked Inhibitor of Apoptosis-associated Factor-1 as an Interferon-stimulated Gene That Augments TRAIL Apo2L-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[63]  J A Frank,et al.  Serial contrast‐enhanced magnetic resonance imaging in patients with early relapsing–remitting multiple sclerosis: Implications for treatment trials , 1994, Annals of neurology.

[64]  R. Kurzrock,et al.  Hairy cell leukaemia: review of treatment , 1991, British journal of haematology.

[65]  J. Lindenmann,et al.  Inheritance of Resistance to Influenza Virus in Mice.∗ , 1964, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[66]  S. Dzik.  The nature of the principal type 1 interferon-producing cells in human blood , 2000 .

[67]  P. Griffiths,et al.  Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[68]  P. Lengyel,et al.  Interferon action: RNA cleavage pattern of a (2'-5')oligoadenylate--dependent endonuclease. , 1981, Science.

[69]  D. Lin,et al.  Directed evolution of gene-shuffled IFN-α molecules with activity profiles tailored for treatment of chronic viral diseases , 2007, Proceedings of the National Academy of Sciences.

[70]  M. Dalakas,et al.  A Study of the Interferon Antiviral Mechanism: Apoptosis Activation by the 2–5A System , 1997, The Journal of experimental medicine.

[71]  J. Farber.  A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[72]  R. N. Harty,et al.  Phospholipid Scramblase 1 Potentiates the Antiviral Activity of Interferon , 2004, Journal of Virology.

[73]  J. Chebath,et al.  Molecular cloning and sequence of partial cDNA for interferon-induced (2'-5')oligo(A) synthetase mRNA from human cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[74]  T. Merigan,et al.  Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. , 1978, The New England journal of medicine.

[75]  Graham M Lord,et al.  Recent developments in the transcriptional regulation of cytolytic effector cells , 2004, Nature Reviews Immunology.

[76]  R. Hirsch,et al.  Treatment of multiple sclerosis with gamma interferon , 1987, Neurology.

[77]  T. Taniguchi,et al.  Antiviral response by natural killer cells through TRAIL gene induction by IFN–α/β  , 2001, European journal of immunology.

[78]  J. Derisi,et al.  Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant , 2006, PLoS pathogens.

[79]  J. Derisi,et al.  An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors , 2007, Proceedings of the National Academy of Sciences.

[80]  D. Barton,et al.  Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. , 2002, RNA.

[81]  G. Stark,et al.  Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells , 1984, Cell.

[82]  中治 美有紀.  IFN-alpha prevents the growth of preneoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat , 2004 .

[83]  R. Gelber,et al.  Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. , 1988, The New England journal of medicine.

[84]  D. Sanan,et al.  Expression of Platelet Glycoprotein (GP) V in Heterologous Cells and Evidence for Its Association with GP Ibα in Forming a GP Ib-IX-V Complex on the Cell Surface (*) , 1995, The Journal of Biological Chemistry.

[85]  E. Borden,et al.  Anticancer Activity of Sodium Stibogluconate in Synergy with IFNs1 , 2002, The Journal of Immunology.

[86]  M. Gore,et al.  Randomized adjuvant therapy trials in melanoma: surgical and systemic. , 2007, Seminars in oncology.

[87]  H. Whittle,et al.  Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[88]  M. Talpaz.  Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. , 2001, Seminars in hematology.

[89]  W. Weimar,et al.  FIBROBLAST INTERFERON IN HBsAg-POSITIVE CHRONIC ACTIVE HEPATITIS , 1977, The Lancet.

[90]  L. O’Neill,et al.  Targeting signal transduction as a strategy to treat inflammatory diseases , 2006, Nature Reviews Drug Discovery.

[91]  G. Hämmerling,et al.  HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. , 1997, Immunity.

[92]  A. Hagenbeek,et al.  Meta-analysis to evaluate the role of interferon in follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  Andrew D. Luster,et al.  γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins , 1985, Nature.

[94]  K. Cantell,et al.  Effects of interferon-alpha on human warts. , 1982, Journal of interferon research.

[95]  Lawrence,et al.  Biological Properties of Recombinant  «-Interfà © rons : 40 th Anniversary of the Discovery of Interferons 1 , 2006 .

[96]  J. Andersen,et al.  The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe? , 2006, Cytokine & growth factor reviews.

[97]  R. Silverman.  Viral Encounters with 2′,5′-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response , 2007, Journal of Virology.

[98]  Roger Williams,et al.  Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. , 2003, Antiviral research.

[99]  J. Barrett,et al.  G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell , 2005, Cancer Immunology, Immunotherapy.

[100]  W. Graham.  Deletions of interferon genes in acute lymphoblastic leukemia. , 1990, The New England journal of medicine.

[101]  A. Albini,et al.  The guanylate binding protein‐1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP‐1 expression , 2003, The EMBO journal.

[102]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[103]  A. Pichlmair,et al.  RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-Phosphates , 2006, Science.

[104]  L. Peltonen.  Old suspects found guilty--the first genome profile of multiple sclerosis. , 2007, The New England journal of medicine.

[105]  K. Wright,et al.  Epigenetic regulation of MHC-II and CIITA genes. , 2006, Trends in immunology.

[106]  M. Gore,et al.  Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.

[107]  J. Nogales-Gaete,et al.  [Treatment of multiple sclerosis with interferons]. , 1996, Revista médica de Chile (Impresa).

[108]  L. Kulik.  Can therapy of hepatitis C affect the development of hepatocellular carcinoma? , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[109]  S. Kotenko,et al.  Full house: 12 receptors for 27 cytokines. , 2004, International immunopharmacology.

[110]  D. Jukic,et al.  Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b , 2007, Clinical Cancer Research.

[111]  G. Stark,et al.  α-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences , 1985, Nature.

[112]  K. Cantell,et al.  TOPICAL THERAPY OF ULCERATIVE HERPETIC KERATITIS WITH HUMAN INTERFERON , 1976, The Lancet.

[113]  R. Champlin,et al.  Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer. , 1988, The American journal of medicine.

[114]  J. Hiscott,et al.  Manipulation of the nuclear factor-κB pathway and the innate immune response by viruses , 2006, Oncogene.

[115]  J. Lindenmann,et al.  Virus interference. I. The interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[116]  E. Waubant,et al.  Interferon beta‐1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis , 1996, Annals of neurology.

[117]  J U Gutterman,et al.  Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[118]  J. Casanova,et al.  Herpes Simplex Virus Encephalitis in Human UNC-93B Deficiency , 2006, Science.

[119]  P. Cresswell,et al.  Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[120]  A. Vogt,et al.  HLA-DM - an endosomal and lysosomal chaperone for the immune system. , 1999, Trends in biochemical sciences.

[121]  R. Schultz,et al.  Similarities of murine gamma interferon and the lymphokine that renders macrophages cytotoxic. , 1982, Journal of interferon research.

[122]  G. Kochs,et al.  Interferon-induced Mx proteins in antiviral host defense. , 2007, Biochimie.

[123]  S. Ugurel,et al.  Heterogenous susceptibility to CD95‐induced apoptosis in melanoma cells correlates with bcl‐2 and bcl‐x expression and is sensitive to modulation by interferon‐γ , 1999, International journal of cancer.

[124]  Naoko Kinukawa,et al.  STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  R. Flavell,et al.  Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[126]  B. Williams,et al.  ISG20, a New Interferon-induced RNase Specific for Single-stranded RNA, Defines an Alternative Antiviral Pathway against RNA Genomic Viruses* , 2003, The Journal of Biological Chemistry.

[127]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[128]  M. Yoneyama,et al.  Cytoplasmic double-stranded DNA sensor , 2007, Nature Immunology.

[129]  S. Chi,et al.  Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses , 2006, Oncogene.

[130]  Christine A. Biron,et al.  Type 1 Interferons and the Virus-Host Relationship: A Lesson in Détente , 2006, Science.

[131]  R. Silverman,et al.  Interferon action and apoptosis are defective in mice devoid of 2′,5′‐oligoadenylate‐dependent RNase L , 1997, The EMBO journal.

[132]  A. Krieg,et al.  Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.

[133]  J. Casanova,et al.  Human primary immunodeficiencies of type I interferons. , 2007, Biochimie.

[134]  P. Seeburg,et al.  The structure of eight distinct cloned human leukocyte interferon cDNAs , 1981, Nature.

[135]  G. Uzé,et al.  IL-28 and IL-29: newcomers to the interferon family. , 2007, Biochimie.

[136]  B. Williams,et al.  Functional classification of interferon‐stimulated genes identified using microarrays , 2001, Journal of leukocyte biology.

[137]  B. Peterlin,et al.  The class II transactivator CIITA is a transcriptional integrator. , 1999, Microbes and infection.

[138]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[139]  Shizuo Akira,et al.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses , 2004, Nature Immunology.

[140]  T. Taniguchi,et al.  Human leukocyte and fibroblast interferons are structurally related , 1980, Nature.

[141]  G. Stark,et al.  Characterization of β-R1, a Gene That Is Selectively Induced by Interferon β (IFN-β) Compared with IFN-α* , 1996, The Journal of Biological Chemistry.

[142]  A. Goldberg,et al.  Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. , 1993, Nature.

[143]  O. Olopade,et al.  Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. , 1993, Cancer research.

[144]  D. Levy,et al.  Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. , 2005, Cancer research.

[145]  M. Hilleman,et al.  Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[146]  Y. Mitsui,et al.  Elucidation of the basic three-dimensional structure of type I interferons and its functional and evolutionary implications. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[147]  J. Vilček,et al.  Two antigenically distinct species of human interferon. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[148]  Xiaoyu Hu,et al.  Sensitization of IFN-γ Jak-STAT signaling during macrophage activation , 2002, Nature Immunology.

[149]  D. Tough,et al.  Modification of TLR‐induced activation of human dendritic cells by type I IFN: synergistic interaction with TLR4 but not TLR3 agonists , 2006, European journal of immunology.

[150]  Simon C Watkins,et al.  Ectopic Expression of Interferon Regulatory Factor-1 Promotes Human Breast Cancer Cell Death and Results in Reduced Expression of Survivin , 2004, Cancer Research.

[151]  H. Dvorak,et al.  Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. , 1989, Journal of the National Cancer Institute.

[152]  M. Esteban,et al.  Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. , 1995, Journal of immunology.

[153]  A. Almasan,et al.  Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. , 2001, Blood.

[154]  G. Sen,et al.  Novel functions of proteins encoded by viral stress-inducible genes. , 2004, Pharmacology & therapeutics.

[155]  S. Ariyan,et al.  Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas , 2004, Cancer Research.

[156]  Richard A Flavell,et al.  Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[157]  I. Kerr,et al.  Differential Responses to IFN-α Subtypes in Human T Cells and Dendritic Cells 12 , 2003, The Journal of Immunology.

[158]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[159]  J. Hoofnagle,et al.  Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. , 1986, The New England journal of medicine.

[160]  G. Stark,et al.  Cell Type-Specific Signaling in Response to Interferon-γ , 2007 .

[161]  S Pestka,et al.  Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. , 1998, Cancer research.

[162]  P. Cresswell,et al.  HLA-DM Interactions with Intermediates in HLA-DR Maturation and a Role for HLA-DM in Stabilizing Empty HLA-DR Molecules , 1996, The Journal of experimental medicine.

[163]  F. Guadagni,et al.  Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  M. Gavutis,et al.  Differential receptor subunit affinities of type I interferons govern differential signal activation. , 2007, Journal of molecular biology.

[165]  A. Blangy,et al.  Interferon-α and -β differentially regulate osteoclastogenesis: Role of differential induction of chemokine CXCL11 expression , 2005 .

[166]  D. Lindner.  Interferons as antiangiogenic agents , 2002, Current oncology reports.

[167]  J. Tschopp,et al.  Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. , 2006, Molecular cell.

[168]  P. Morris.  An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules , 1994 .

[169]  L. Durelli,et al.  Interferon treatment for multiple sclerosis , 1998, Neurology.

[170]  R. Schreiber,et al.  Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function1 , 2007, The Journal of Immunology.

[171]  A. Richmond,et al.  The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[172]  Diego Jaitin,et al.  An Interferon α2 Mutant Optimized by Phage Display for IFNAR1 Binding Confers Specifically Enhanced Antitumor Activities* , 2007, Journal of Biological Chemistry.

[173]  J. Albrecht,et al.  Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. , 1986, The New England journal of medicine.

[174]  Stefano Volinia,et al.  Interferon modulation of cellular microRNAs as an antiviral mechanism , 2007, Nature.

[175]  K. Knobeloch,et al.  IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses , 2007, Proceedings of the National Academy of Sciences.

[176]  G. Sen,et al.  Transcriptional signaling by double-stranded RNA: role of TLR3. , 2005, Cytokine & growth factor reviews.

[177]  A. Zilberstein,et al.  Isolation of two interferon-induced translational inhibitors: a protein kinase and an oligo-isoadenylate synthetase. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[178]  J. Manola,et al.  A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.

[179]  S. Hayward,et al.  Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[180]  B. Blumberg.  Australia antigen and the biology of hepatitis B. , 1977, Science.

[181]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[182]  B. Wiedenmann,et al.  Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. , 2003, Journal of the National Cancer Institute.

[183]  K. Okumura,et al.  Type I Interferons (IFNs) Regulate Tumor Necrosis Factor–related Apoptosis-inducing Ligand (TRAIL) Expression on Human T Cells: A Novel Mechanism for the Antitumor Effects of  Type I IFNs , 1999, The Journal of experimental medicine.

[184]  Diego Jaitin,et al.  Inquiring into the Differential Action of Interferons (IFNs): an IFN-α2 Mutant with Enhanced Affinity to IFNAR1 Is Functionally Similar to IFN-β , 2006, Molecular and Cellular Biology.

[185]  M. Katze,et al.  Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. , 1997, Virology.

[186]  J. Mills,et al.  Interferon Therapy for Condylomata Acuminata , 1987 .

[187]  T. Merigan,et al.  Inhibition of respiratory virus infection by locally applied interferon. , 1973, Lancet.

[188]  K. Früh,et al.  Antigen presentation by MHC class I and its regulation by interferon gamma. , 1999, Current opinion in immunology.

[189]  B. Williams,et al.  Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis , 2003, Apoptosis.

[190]  H. Buttenschøn,et al.  The interferon alpha induced protein ISG12 is localized to the nuclear membrane. , 2001, European journal of biochemistry.

[191]  Yulan Qing,et al.  Alternative Activation of STAT1 and STAT3 in Response to Interferon-γ* , 2004, Journal of Biological Chemistry.

[192]  R. Betts,et al.  Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans. , 1987, The Journal of infectious diseases.

[193]  D. Tyrrell,et al.  Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers , 1983, Antimicrobial Agents and Chemotherapy.

[194]  S. Lemon,et al.  Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[195]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[196]  B. Medoff,et al.  STAT1 in Peripheral Tissue Differentially Regulates Homing of Antigen-Specific Th1 and Th2 Cells1 , 2006, The Journal of Immunology.

[197]  Shizuo Akira,et al.  Antiviral signaling through pattern recognition receptors. , 2006, Journal of biochemistry.

[198]  J. Armstrong,et al.  Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. , 1979, The New England journal of medicine.

[199]  J. Skehel,et al.  Interferon action—sequence specificity of the ppp(A2′p)nA-dependent ribonuclease , 1981, Nature.

[200]  W. K. Roberts,et al.  Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis , 1976, Nature.

[201]  Robert H. Silverman,et al.  Expression cloning of 2-5A-dependent RNAase: A uniquely regulated mediator of interferon action , 1993, Cell.

[202]  Knobler Rl.  Systemic interferon therapy of multiple sclerosis: the pros. , 1988 .

[203]  James G. Boyd,et al.  Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.

[204]  Lena Alexopoulou,et al.  Detrimental Contribution of the Toll-Like Receptor (TLR)3 to Influenza A Virus–Induced Acute Pneumonia , 2006, PLoS pathogens.

[205]  G. Sen,et al.  PACT, a protein activator of the interferon‐induced protein kinase, PKR , 1998, The EMBO journal.

[206]  C. Samuel,et al.  Antiviral Actions of Interferons , 2001, Clinical Microbiology Reviews.

[207]  E. Coccia,et al.  Viral infection and Toll‐like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte‐derived dendritic cells , 2004, European journal of immunology.

[208]  Parvin Mousavi,et al.  Genome-Wide Network Analysis Reveals the Global Properties of IFN-β Immediate Transcriptional Effects in Humans12 , 2007, The Journal of Immunology.

[209]  R. Silverman,et al.  Small-molecule activators of RNase L with broad-spectrum antiviral activity , 2007, Proceedings of the National Academy of Sciences.

[210]  E. Borden,et al.  A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. , 1991, Journal of immunology.

[211]  E. Coccia,et al.  Differential responsiveness to IFN‐α and IFN‐β of human mature DC through modulation of IFNAR expression , 2006 .

[212]  I. Kerr,et al.  Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon , 1990, Cell.

[213]  P. Itin,et al.  Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. , 1997, The Journal of clinical investigation.

[214]  P. Pitha,et al.  Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[215]  K. Honda,et al.  Type I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors , 2006 .

[216]  J. Carton,et al.  Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. , 1999, Virology.

[217]  A. Ascherio,et al.  Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors , 2007, Annals of neurology.

[218]  E. Borden,et al.  Preferential Induction of Apoptosis by Interferon (IFN)-β Compared with IFN-α2 , 2001 .

[219]  J. Hoofnagle,et al.  Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B , 1988 .

[220]  A. Ballestrero,et al.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells , 2004, Clinical Cancer Research.

[221]  L. Gerace,et al.  Phospholipid scramblase 1 is imported into the nucleus by a receptor-mediated pathway and interacts with DNA. , 2004, Biochemistry.

[222]  J. Justesen,et al.  Small ISGs coming forward. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[223]  B. Peterlin,et al.  Expression of MHC II genes. , 2006, Current topics in microbiology and immunology.

[224]  B. Williams,et al.  PKR; a sentinel kinase for cellular stress , 1999, Oncogene.

[225]  P. Walsh,et al.  RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. , 2003, The Journal of urology.

[226]  C. Tannenbaum,et al.  Immune-inflammatory mechanisms in IFNγ-mediated anti-tumor activity , 2000 .

[227]  K. Weiss.  Safety profile of interferon-alpha therapy. , 1998, Seminars in oncology.

[228]  P. Sims,et al.  Molecular Cloning of Human Plasma Membrane Phospholipid Scramblase , 1997, The Journal of Biological Chemistry.

[229]  W. Reith,et al.  Mini‐review: Specificity and expression of CIITA, the master regulator of MHC class II genes , 2004, European journal of immunology.

[230]  S. Ramanujam,et al.  In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. , 1996, Journal of immunology.

[231]  R. Ransohoff,et al.  Alternative and accessory pathways in the regulation of IFN-beta-mediated gene expression. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[232]  G. Foster,et al.  IFN-α Subtypes Differentially Affect Human T Cell Motility1 , 2004, The Journal of Immunology.

[233]  I. Kerr,et al.  pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[234]  G. Schreiber,et al.  The receptor of the type I interferon family. , 2007, Current topics in microbiology and immunology.

[235]  R. Roberts,et al.  New and atypical families of type I interferons in mammals: comparative functions, structures, and evolutionary relationships. , 1997, Progress in nucleic acid research and molecular biology.

[236]  L. Ivashkiv,et al.  Role of STAT3 in Type I Interferon Responses , 2006, Journal of Biological Chemistry.

[237]  I. Leukemia.  Long term follow up of the italian trial of Interferon-A versus conventional chemotherapy in Chronic Myeloid Leukemia , 1998 .

[238]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[239]  G. Foster.  Past, present, and future hepatitis C treatments. , 2004, Seminars in liver disease.

[240]  B. Williams,et al.  Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays , 1998 .

[241]  H. Strander,et al.  Use of interferon-α in laryngeal papillomatosis: eight years of the Cuban national programme , 1997, The Journal of Laryngology & Otology.

[242]  R. Hirsch,et al.  EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON , 1987, The Lancet.

[243]  Yan A. Su,et al.  Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma , 1997, Oncogene.

[244]  J. Metcalf,et al.  Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. , 1990 .

[245]  C. Bucana,et al.  Evidence for the causal role of endogenous interferon-α/β in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms , 2004, Clinical & Experimental Metastasis.

[246]  R. Rudick,et al.  Interferon‐β for multiple sclerosis: Long‐term benefits? , 2007 .

[247]  G. Scott,et al.  PREVENTION OF RHINOVIRUS COLDS BY HUMAN INTERFERON ALPHA-2 FROM ESCHERICHIA COLI , 1982, The Lancet.

[248]  Wei Zheng,et al.  Age-Dependent Resistance to Lethal Alphavirus Encephalitis in Mice: Analysis of Gene Expression in the Central Nervous System and Identification of a Novel Interferon-Inducible Protective Gene, Mouse ISG12 , 2002, Journal of Virology.

[249]  G. Fantuzzi,et al.  Spontaneous and inducible cytokine responses in healthy humans receiving a single dose of IFN-alpha2b: increased production of interleukin-1 receptor antagonist and suppression of IL-1-induced IL-8. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[250]  G. Stark,et al.  Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.

[251]  Vincent Ferretti,et al.  A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis , 2005, Nature Genetics.

[252]  F. Shi,et al.  Reciprocal regulation between natural killer cells and autoreactive T cells , 2006, Nature Reviews Immunology.

[253]  S. Tyring,et al.  Imiquimod, a Patient-Applied Immune-Response Modifier for Treatment of External Genital Warts , 1998, Antimicrobial Agents and Chemotherapy.

[254]  T. Maniatis,et al.  Multiple Functions of the IKK-Related Kinase IKKε in Interferon-Mediated Antiviral Immunity , 2007, Science.

[255]  G R Stark,et al.  Characterization of a human gene inducible by alpha‐ and beta‐interferons and its expression in mouse cells. , 1986, The EMBO journal.

[256]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.

[257]  A. Feldman,et al.  Interferon γ–Inducible Protein 10 Selectively Inhibits Proliferation and Induces Apoptosis in Endothelial Cells , 2006, Annals of Surgical Oncology.

[258]  T. Maniatis,et al.  Identification of two distinct regulatory regions adjacent to the human β-interferon gene , 1983, Cell.

[259]  J. Neefjes,et al.  The ins and outs of intracellular peptides and antigen presentation by MHC class I molecules. , 2005, Current topics in microbiology and immunology.

[260]  S. Nagata,et al.  At least three human type alpha interferons: structure of alpha 2. , 1980, Science.

[261]  B. McMahon,et al.  Chronic hepatitis B. , 2002, The New England journal of medicine.

[262]  G. Stark,et al.  Requirement of Phosphoinositide 3-Kinase and Akt for Interferon-β-mediated Induction of the β-R1(SCYB11) Gene* , 2002, The Journal of Biological Chemistry.

[263]  S. Kitareewan,et al.  Microarray Analyses Uncover UBE1L as a Candidate Target Gene for Lung Cancer Chemoprevention , 2004, Cancer Research.

[264]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[265]  Yong Liu,et al.  Functionally Distinct Double-stranded RNA-binding Domains Associated with Alternative Splice Site Variants of the Interferon-inducible Double-stranded RNA-specific Adenosine Deaminase* , 1997, The Journal of Biological Chemistry.

[266]  T. Merigan,et al.  Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. , 1976, The New England journal of medicine.

[267]  Elke Krüger,et al.  Interferon‐γ, the functional plasticity of the ubiquitin–proteasome system, and MHC class I antigen processing , 2005, Immunological reviews.

[268]  O. Haller,et al.  Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[269]  S. Kong,et al.  Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. , 2007, Arthritis and rheumatism.

[270]  N. Kadowaki,et al.  The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.

[271]  K. Ishii,et al.  Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses , 2006, Nature.

[272]  S. Harrison,et al.  An Atomic Model of the Interferon-β Enhanceosome , 2007, Cell.

[273]  M. Gale,et al.  Alpha Interferon Induces Distinct Translational Control Programs To Suppress Hepatitis C Virus RNA Replication , 2003, Journal of Virology.

[274]  U. Ritz,et al.  Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[275]  R. Silverman,et al.  The role of 2′-5′ oligoadenylate-activated ribonuclease L in apoptosis , 1998, Cell Death and Differentiation.

[276]  P. Cresswell,et al.  Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. , 1994, Immunity.

[277]  B. Williams.  Signal Integration via PKR , 2001, Science's STKE.

[278]  H. Strander,et al.  Interferon-α as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series , 2005, Acta oncologica.